A Prostate Cancer diagnosis turned life upside down for Lisburn man Stuart Rainey, bringing fear, uncertainty and countless ...
Cancer biology increasingly recognizes the profound impact of sex-specific factors in shaping tumor development, progression, and therapeutic outcomes.
Combination therapy led to complete remission in more than 50% of mice with different tumor types, many of which were resistant to ICB therapy alone.
New findings from VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM), published in ...
By partnering with other like-minded organizations to fund targeted RFAs throughout the year, ACS is able to invest in new ...
The sidelining by U. of the advisory panel that decides access to free preventive healthcare is delaying updates to screening ...
Join Tom and Mike as they share an important update on Tom's prostate cancer journey. In this video, they discuss Tom's ...
Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed a set of novel, ...
Based on the efficacy and safety data, Oric will advance the 400mg therapy to Phase III trials, with more treatment-emergent ...
The combination of talazoparib and enzalutamide demonstrated a statistically significant improvement in radiographic ...
Oric Pharmaceuticals has picked the phase 3 dose for its prostate cancer prospect, barreling into the pivotal program while ...
ORIC Pharmaceuticals (ORIC) stock slides as the company posts early-stage trial data for its experimental prostate cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results